Study to Assess the Safety, Tolerability, and Effects of CHI-202 to Support Recovery From Physical Activity

A Randomized, Double-Blind, Placebo-Controlled, Repeated-Dose Study to Assess the Safety, Tolerability, and Effects of CHI-202 to Support Recovery From Physical Activity

The study is designed as a proof of concept, single-center, randomized, double-blind, placebo controlled study to assess the safety and efficacy of CHI-202 (cannabinoids and other ingredients) compared to placebo in the treatment of Delayed Onset Muscle Soreness (DOMS).

Study Overview

• Status: Completed
• Conditions: Delayed Onset Muscle Soreness (DOMS)
• Intervention / Treatment: Dietary supplement: CHI-202; Dietary supplement: CHI-101

Detailed Description

The study is designed as a proof of concept, single-center, randomized, double-blind, placebo controlled study to assess the safety and efficacy of CHI-202 (cannabinoids and other ingredients) compared to placebo in the treatment of Delayed Onset Muscle Soreness (DOMS). Healthy adults ages 18-65 years who are exercise-trained (self-report exercising at least 3 times per week for at least 30 minutes per session for the past year) will be recruited from existing panels of participants from past studies, local advertisements, and social media targeted advertisements. Those who meet the inclusion/exclusion criteria will be enrolled into the study, scheduled for the Exercise Visit (Study Visit 1; Day 0) within 2 weeks of screening, and randomized to active vs. placebo IP condition in a 1:1 ratio. One repetition maximum (1RM) method, the maximum amount of weight one can lift in a single repetition for a given exercise, will be used in order to induce DOMS. Following the completion of the Exercise Visit, participants will be scheduled for 3 follow-up visits that will occur 1, 2, and 3 days post-Exercise Visit. Participants will consume 7 scheduled doses of the study IP to which they have been randomly assigned (i.e., active or placebo) with instruction to consume the study IP prior to the exercise at Study Visit 1, at 8PM (±1 hour) that night, and then at 8AM and 8PM (±1 hour) every day until their final study visit. The last dose will occur at 8AM (±1 hour) on Day 4, i.e., immediately prior to Study Visit 4.

• Study Type: Interventional
• Enrollment (Actual): 40
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • Florida
    • Boca Raton, Florida, United States, 33432
      • International Society for Sports Nutrition

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Is a healthy adult aged 18-65 years, inclusive, at the time of screening.
2. Is exercise-trained, i.e., self-reports exercising at least 3 times per week for at least 30 minutes per session for the past year.
3. Has a body mass index between 18 and 35 kg/m2 (inclusive).
4. Is judged by the Investigator to be in generally good health at screening based on participants' self-reported medical history.
5. Must be adequately informed of the nature and risks of the study and give written informed consent prior to screening.

Exclusion Criteria:

1. Women who are pregnant, lactating, breastfeeding, or planning a pregnancy.
2. Women of childbearing potential, or men who are sexually active with a woman of childbearing potential, who are unwilling or unable to use an acceptable method of contraception (abstinence or the use of a highly effective method of contraception, including hormonal contraception, diaphragm, cervical cap, vaginal sponge, condom, vasectomy, or intrauterine device) from at least 21 days prior to the first dose of study medication until 28 days after the last dose of study medication.
3. Has a history of epilepsy, hepatitis, clinically significant hepatic or renal impairment, or human immunodeficiency virus.
4. Changes in the use of a prescription, over-the-counter (OTC), systemic or topical drug(s), herbal supplement(s), or vitamin(s) for the month prior to the Exercise Visit.
5. Has any clinically significant condition or abnormal finding at screening that would, in the opinion of the Investigator, preclude study participation or interfere with the evaluation of the study IP.
6. Has a history of a known significant allergic condition, significant drug-related hypersensitivity, or allergic reaction to any compound or chemical class related to cannabis, including phytocannabinoids and cannabinoid analogues, or excipients utilized within the IP (e.g., coconut; coconut oil; medium-chain triglycerides).
7. Has musculoskeletal issues that might impede performing maximal elbow flexion exercises.
8. Has taken a medication with likely CBD-interactions, including warfarin, clobazam, valproic acid, phenobarbital, mTOR inhibitors, oral tacrolimus, and St. John's Wort within 30 days of the Exercise Visit or during the study.
9. Has taken grapefruit products and/or Seville oranges within the 7 days prior to dosing with study IP.
10. Has used cannabis, synthetic cannabinoid or cannabinoid analogues (e.g., dronabinol, nabilone), hemp products, synthetic cannabinoid receptor agonists (e.g., spice, K2), or any CBD- or THC-containing product (e.g., Sativex, Epidiolex) within 4 weeks of the Exercise Visit or during the study.
11. Has a history or current diagnosis of a significant psychiatric disorder that would, in the opinion of the Investigator, affect the subject's ability to comply with the study requirements.
12. Endorses current suicidal intent.
13. Has participated in any investigational product or device study within 30 days prior to the Screening Visit, or is scheduled to participate in another investigational product or device study during the course of this study.
14. Demonstrates behavior indicating unreliability or inability to comply with the requirements of the protocol.
15. Has a positive result on urine drug screen for cocaine, amphetamine, methamphetamine, THC, and opiates at the first study visit.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Active; CHI-202. Participants will drink one 7.0g CHI-202 powder sachet mixed into 16oz of water twice daily.	Dietary supplement: CHI-202; Blend of cannabinoids & other ingredients
Placebo Comparator: Placebo; CHI-101. Participants will drink one 7.0g CHI-101 powder sachet mixed into 16oz of water twice daily.	Dietary supplement: CHI-101; Placebo

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Changes from baseline in blood pressure (mmHg) [Safety and Tolerability]	Blood pressure is measure by the combination of systolic and diastolic measurements	Day 2
Changes from baseline in blood pressure (mmHg) [Safety and Tolerability]	Blood pressure is measure by the combination of systolic and diastolic measurements	Day 3
Changes from baseline in blood pressure (mmHg) [Safety and Tolerability]	Blood pressure is measure by the combination of systolic and diastolic measurements	Day 4
Changes from baseline in respiratory rate (breaths per minute) [Safety and Tolerability]	Respiratory rate will be measured as breaths per minute	Day 2
Changes from baseline in respiratory rate (breaths per minute) [Safety and Tolerability]	Respiratory rate will be measured as breaths per minute	Day 3
Changes from baseline in respiratory rate (breaths per minute) [Safety and Tolerability]	Respiratory rate will be measured as breaths per minute	Day 4
Changes from baseline in heart rate (beats per minute) [Safety and Tolerability]	Heart rate will be measured as heart beats per minute	Day 2
Changes from baseline in heart rate (beats per minute) [Safety and Tolerability]	Heart rate will be measured as heart beats per minute	Day 3
Changes from baseline in heart rate (beats per minute) [Safety and Tolerability]	Heart rate will be measured as heart beats per minute	Day 4
Total number of Adverse Events [Safety and Tolerability]	Safety and tolerability will be assessed through Adverse Events and Serious Adverse Events	Through study completion (Day 4)
Total number of participants with Adverse Events [Safety and Tolerability]	Safety and tolerability will be assessed through Adverse Events and Serious Adverse Events	Through study completion (Day 4)
Compliance with IP consumption (total # of self-reported doses consumed/maximum of 7 total possible doses consumed) [Safety and Tolerability]	Safety and tolerability will be assessed through Compliance with IP consumption (total # of self-reported doses consumed/maximum of 7 total possible doses consumed)	Through study completion (Day 4)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Average soreness or discomfort intensity using the 11-point (0-10) NRS	Self-reported average soreness or discomfort intensity using 11-point (0-10) NRS where 10 is most soreness/discomfort intensity	Day 1 - post DOMS intervention
Average soreness or discomfort intensity over the last 24 hours using the 11-point (0-10) NRS	Self-reported average soreness or discomfort intensity over the last 24 hours using 11-point (0-10) NRS where 10 is most soreness/discomfort intensity	Day 2
Average soreness or discomfort intensity over the last 24 hours using the 11-point (0-10) NRS	Self-reported average soreness or discomfort intensity over the last 24 hours using 11-point (0-10) NRS where 10 is most soreness/discomfort intensity	Day 3
Average soreness or discomfort intensity over the last 24 hours using the 11-point (0-10) NRS	Self-reported average soreness or discomfort intensity over the last 24 hours using 11-point (0-10) NRS where 10 is most soreness/discomfort intensity	Day 4
Worst soreness or discomfort intensity using the 11-point (0-10) NRS	Self-reported worst soreness or discomfort intensity using the 11-point (0-10) NRS where 10 is most soreness/discomfort intensity	Day 1 - post DOMS intervention
Worst soreness or discomfort intensity over the last 24 hours using the 11-point (0-10) NRS	Self-reported worst soreness or discomfort intensity over the last 24 hours using the 11-point (0-10) NRS where 10 is most soreness/discomfort intensity	Day 2
Worst soreness or discomfort intensity over the last 24 hours using the 11-point (0-10) NRS	Self-reported worst soreness or discomfort intensity over the last 24 hours using the 11-point (0-10) NRS where 10 is most soreness/discomfort intensity	Day 3
Worst soreness or discomfort intensity over the last 24 hours using the 11-point (0-10) NRS	Self-reported worst soreness or discomfort intensity over the last 24 hours using the 11-point (0-10) NRS where 10 is most soreness/discomfort intensity	Day 4
Average stiffness intensity using the 11-point (0-10) NRS	Self-reported average stiffness intensity using the 11-point (0-10) NRS where 10 is most stiffness intensity	Day 1 - post DOMS intervention
Average stiffness intensity over the last 24 hours using the 11-point (0-10) NRS	Self-reported average stiffness intensity over the last 24 hours using the 11-point (0-10) NRS where 10 is most stiffness intensity	Day 2
Average stiffness intensity over the last 24 hours using the 11-point (0-10) NRS	Self-reported average stiffness intensity over the last 24 hours using the 11-point (0-10) NRS where 10 is most stiffness intensity	Day 3
Average stiffness intensity over the last 24 hours using the 11-point (0-10) NRS	Self-reported average stiffness intensity over the last 24 hours using the 11-point (0-10) NRS where 10 is most stiffness intensity	Day 4
Worst stiffness intensity using the 11-point (0-10) NRS	Self-reported worst stiffness intensity using the 11-point (0-10) NRS where 10 is most stiffness intensity	Day 1 - post DOMS intervention
Worst stiffness intensity over the last 24 hours using the 11-point (0-10) NRS	Self-reported worst stiffness intensity over the last 24 hours using the 11-point (0-10) NRS where 10 is most stiffness intensity	Day 2
Worst stiffness intensity over the last 24 hours using the 11-point (0-10) NRS	Self-reported worst stiffness intensity over the last 24 hours using the 11-point (0-10) NRS where 10 is most stiffness intensity	Day 3
Worst stiffness intensity over the last 24 hours using the 11-point (0-10) NRS	Self-reported worst stiffness intensity over the last 24 hours using the 11-point (0-10) NRS where 10 is most stiffness intensity	Day 4
Interference of soreness, discomfort, or stiffness after exercise on the ability to perform daily activities at home or at work over the last 24 hours using the 11-point (0-10) NRS	Self-reported interference of soreness, discomfort, or stiffness after exercise on the ability to perform daily activities at home or at work over the last 24 hours using the 11-point (0-10) NRS where 10 is most interference	Day 2
Interference of soreness, discomfort, or stiffness after exercise on the ability to perform daily activities at home or at work over the last 24 hours using the 11-point (0-10) NRS	Self-reported interference of soreness, discomfort, or stiffness after exercise on the ability to perform daily activities at home or at work over the last 24 hours using the 11-point (0-10) NRS where 10 is most interference	Day 3
Interference of soreness, discomfort, or stiffness after exercise on the ability to perform daily activities at home or at work over the last 24 hours using the 11-point (0-10) NRS	Self-reported interference of soreness, discomfort, or stiffness after exercise on the ability to perform daily activities at home or at work over the last 24 hours using the 11-point (0-10) NRS where 10 is most interference	Day 4
Interference of soreness, discomfort, or stiffness after exercise on the ability to participate in physical activities over the last 24 hours using the 11-point (0-10) NRS	Self-reported interference of soreness, discomfort, or stiffness after exercise on the ability to participate in physical activities over the last 24 hours using the 11-point (0-10) NRS where 10 is most interference	Day 2
Interference of soreness, discomfort, or stiffness after exercise on the ability to participate in physical activities over the last 24 hours using the 11-point (0-10) NRS	Self-reported interference of soreness, discomfort, or stiffness after exercise on the ability to participate in physical activities over the last 24 hours using the 11-point (0-10) NRS where 10 is most interference	Day 3
Interference of soreness, discomfort, or stiffness after exercise on the ability to participate in physical activities over the last 24 hours using the 11-point (0-10) NRS	Self-reported interference of soreness, discomfort, or stiffness after exercise on the ability to participate in physical activities over the last 24 hours using the 11-point (0-10) NRS where 10 is most interference	Day 4
Self-reported sleep quality using the 11-point (0-10) NRS	Self-reported sleep quality using the 11-point (0-10) NRS where 10 is best sleep quality	Day 2
Self-reported sleep quality using the 11-point (0-10) NRS	Self-reported sleep quality using the 11-point (0-10) NRS where 10 is best sleep quality	Day 3
Self-reported sleep quality using the 11-point (0-10) NRS	Self-reported sleep quality using the 11-point (0-10) NRS where 10 is best sleep quality	Day 4
Self-reported sleep duration via a sleep diary	Self-reported sleep duration measured in minutes via a sleep diary	Day 2
Self-reported latency to sleep onset via a sleep diary	Self-reported latency to sleep onset measured in minutes via a sleep diary	Day 2
Self-reported sleep continuity via a sleep diary	Self-reported sleep continuity measured in minutes via a sleep diary	Day 2
Self-reported alertness upon waking via a sleep diary	Self-reported alertness upon waking via a sleep diary. Alertness is measure on a scale of 1 to 3 where 1 is Alert, 2 is Alert but a little tired and 3 is Sleepy	Day 2
Self-reported sleep duration via a sleep diary	Self-reported sleep duration measured in minutes via a sleep diary	Day 3
Self-reported latency to sleep onset via a sleep diary	Self-reported latency to sleep onset measured in minutes via a sleep diary	Day 3
Self-reported sleep continuity via a sleep diary	Self-reported sleep continuity measured in minutes via a sleep diary	Day 3
Self-reported alertness upon waking via a sleep diary	Self-reported alertness upon waking via a sleep diary. Alertness is measure on a scale of 1 to 3 where 1 is Alert, 2 is Alert but a little tired and 3 is Sleepy	Day 3
Self-reported sleep duration via a sleep diary	Self-reported sleep duration measured in minutes via a sleep diary	Day 4
Self-reported latency to sleep onset via a sleep diary	Self-reported latency to sleep onset measured in minutes via a sleep diary	Day 4
Self-reported sleep continuity via a sleep diary	Self-reported sleep continuity measured in minutes via a sleep diary	Day 4
Self-reported alertness upon waking via a sleep diary	Self-reported alertness upon waking via a sleep diary. Alertness is measure on a scale of 1 to 3 where 1 is Alert, 2 is Alert but a little tired and 3 is Sleepy	Day 4
Pressure threshold	Pressure threshold measured with a 25-lb algometer	Day 1 - post DOMS intervention
Pressure threshold	Pressure threshold measured with a 25-lb algometer	Day 2
Pressure threshold	Pressure threshold measured with a 25-lb algometer	Day 3
Pressure threshold	Pressure threshold measured with a 25-lb algometer	Day 4
Relaxed elbow angle	Relaxed elbow angle measured with a goniometer in degrees	Day 1 - post DOMS intervention
Active range of motion	Active range of motion measured with a goniometer in degrees	Day 1 - post DOMS intervention
Passive range of motion	Passive range of motion measured with a goniometer in degrees	Day 1 - post DOMS intervention
Relaxed elbow angle	Relaxed elbow angle measured with a goniometer in degrees	Day 2
Active range of motion	Active range of motion measured with a goniometer in degrees	Day 2
Passive range of motion	Passive range of motion measured with a goniometer in degrees	Day 2
Relaxed elbow angle	Relaxed elbow angle measured with a goniometer in degrees	Day 3
Active range of motion	Active range of motion measured with a goniometer in degrees	Day 3
Passive range of motion	Passive range of motion measured with a goniometer in degrees	Day 3
Relaxed elbow angle	Relaxed elbow angle measured with a goniometer in degrees	Day 4
Active range of motion	Active range of motion measured with a goniometer in degrees	Day 4
Passive range of motion	Passive range of motion measured with a goniometer in degrees	Day 4
Muscle circumference	Muscle circumference	Day 1 - post DOMS intervention
Muscle circumference	Muscle circumference	Day 2
Muscle circumference	Muscle circumference	Day 3
Muscle circumference	Muscle circumference	Day 4
Mood using the Profile of Mood States	Mood using the Profile of Mood States	Day 1 - post DOMS intervention
Mood using the Profile of Mood States	Mood using the Profile of Mood States	Day 2
Mood using the Profile of Mood States	Mood using the Profile of Mood States	Day 3
Mood using the Profile of Mood States	Mood using the Profile of Mood States	Day 4

Collaborators and Investigators

• Sponsor: Canopy Growth Corporation
• Investigators: Study Director: Erica Peters, PhD, Canopy Growth Corporation

Study record dates

Study Major Dates

• Study Start (Actual): December 13, 2021
• Primary Completion (Actual): February 4, 2022
• Study Completion (Actual): February 4, 2022

Study Registration Dates

• First Submitted: July 26, 2021
• First Submitted That Met QC Criteria: August 23, 2021
• First Posted (Actual): August 30, 2021

Study Record Updates

• Last Update Posted (Actual): February 16, 2022
• Last Update Submitted That Met QC Criteria: February 15, 2022
• Last Verified: February 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Nervous System Diseases; Pain; Neurologic Manifestations; Musculoskeletal Diseases; Muscular Diseases; Neuromuscular Diseases; Musculoskeletal Pain; Myalgia
• Other Study ID Numbers: 710US-1311

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No